Mann Kind Corporation (NASDAQ:MNKD) saw a large increase in short interest in January. As of March 14th, there was short interest totalling 63,558,514 shares, an increase of 7.3% from the February 28th total of 59,244,446 shares, AR Network reports. Based on an average daily trading volume, of 6,342,384 shares, the days-to-cover ratio is currently 10.0 days. Currently, 31.5% of the shares of the stock are sold short.A number of analysts have recently weighed in on MNKD shares. Analysts at Piper Jaffray downgraded shares of MannKind from a “neutral” rating to an “underweight” rating in a research note on Monday. Mann Kind Corporation (NASDAQ:MNKD) shares after opening at $4.44 moved to $4.60 on last trade day and at the end of the day closed at $4.02. Company price to cash ratio in past twelve months was calculated as 21.42. Mann Kind Corporation (NASDAQ:MNKD) showed a negative weekly performance of -31.98%.
Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) recently declared the top line outcome of the 12-month Phase II Imaging trial in Alzheimer’s Disease (“IMAGINE” Trial), based on draft outcome. Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) shares fell-71.60% in last trading session and ended the day on $2.80.PRAN return on equity ratio is recorded as -143.60% and its return on assets is -113.60%.Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) yearly performance is 23.35%.
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) shares were under investors focus on Monday as they were falling down the gill after hiking almost 18% on Friday. Shares were hammered badly on initial trading session and fell 9% during midday. This snaps the recent downtrend for the firm as the stock is now down almost 19% in the past one-month time frame. Idera Pharmaceuticals Inc (NASDAQ:IDRA) shares moved down 10.72% in last trading session and was closed at $4.08, while trading in range of $ 4.00 – 4.50. Idera Pharmaceuticals Inc (NASDAQ:IDRA) year to date (YTD) performance is -11.88%.
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN)’s shares dropped 3.51% to $1.10. The company on Mar. 24 provided an overview of its three clinical development programs and financial results for the year ended December 31, 2013. For the year ended December 31, 2013, total operating expenses were $8.0 million. Rexahn’s cash and investments totaled $19.0 million as of December 31, 2013, as compared to $14.7 million on December 31, 2012. The increase of $4.3 million was primarily due to $12.3 million from the issuance of common stock and the exercise of stock warrants and options, offset by $8.0 million of net cash used in operating activities. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) weekly performance is -16.28%. On last trading day company shares ended up $1.08. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) distance from 50-day simple moving average (SMA50) is -6.57%. Analysts mean target price for the company is $2.50.